Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson’s disease
Clinica Chimica Acta · 2025-01 · 565 · 119975
DOI: 10.1016/j.cca.2024.119975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinica Chimica Acta, 2025-01. Verfasst von Ying Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Multiple System Atrophy, Supranuclear Palsy, Progressive, Biomarkers, Parkinson Disease. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fuzhou Science and Technology Bureau, Fujian Provincial Department of Science and Technology.
Abstract (Originalsprache)
OBJECTIVES: This study aimed to evaluate the diagnostic ability of six plasma biomarkers in progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and different subtypes of Parkinson's disease (PD). METHODS: Neurofilament light chain (NfL), phosphorylated tau-181, glial fibrillary acidic protein (GFAP), amyloid-β 42 (Aβ42), and amyloid-β 40 (Aβ40) levels were measured using the single-molecule array (Simoa) technique in a cohort of patients with PSP, MSA, different subtypes of PD, and healthy controls (HCs). RESULTS: Plasma NfL and GFAP levels were beneficial in discriminating between the disease groups and HCs. Plasma NfL, Aβ42, and Aβ40 could distinguish atypical Parkinsonian syndrome (APS) from PD and its subtypes. GFAP could discriminate APS from tremor dominant PD but could not discriminate APS from postural instability and gait disorder dominant PD. The efficacy of differentiation improved when a combination of multiple plasma biomarkers was applied. CONCLUSIONS: In this study, the plasma biomarkers NfL, GFAP, Aβ42, and Aβ40 exhibited high discriminatory diagnostic value in PD and APS, and could be used as clinically potential diagnostic biomarkers. Plasma biomarker combinations could improve the differential diagnostic efficacy in the comparisons of PD and APS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China. Electronic address: unionqyye8@fjmu.edu.cn.
Förderung
- Fuzhou Science and Technology Bureau
- Fujian Provincial Department of Science and Technology
Zitieren
APA
Chen, Y., Huang, J., Li, Y., Chen, X., & Ye, Q. (2025). Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson’s disease. Clinica Chimica Acta, 565, 119975. https://doi.org/10.1016/j.cca.2024.119975
Vancouver
Chen Y, Huang J, Li Y, Chen X, Ye Q. Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson’s disease. Clinica Chimica Acta. 2025;565:119975. doi:10.1016/j.cca.2024.119975
BibTeX
@article{Chen2025,
author = {Chen, Ying and Huang, Jieming and Li, Yiming and Chen, Xiaochun and Ye, Qinyong},
title = {Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson’s disease},
journal = {Clinica Chimica Acta},
year = {2025},
volume = {565},
pages = {119975},
doi = {10.1016/j.cca.2024.119975}
}
EUVIMED